Backed by KKR and Viking, BridgeBio (BBIO) is developing a portfolio of 16 therapies for genetically-caused diseases through 20 wholly- and partly-owned subsidiaries.
Its lead candidate, oral BBP-265 for transthyretin amyloid cardiomyopathy (ATTR), a complex disease of aging that results in organ failure, is beginning a Phase 3 trial led by a 62%-owned subsidiary, publicly traded Eidos Therapeutics (EIDX).
Here are three other things you need to know about BridgeBio:
1. The initial indication that will be sought by BBP-265 for ATTR-CM affects 100,000 in the US and may be underdiagnosed.
2. Pfizer got FDA approvals for two oral ATTR therapies, Vyndaqel and Vyndamax, in May 2019.
3. Bridge has development plans for 15 other candidates.
Image Source: BridgeBio SEC Filing
Coming soon: Adaptive Biotechnologies (ADPT)
To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.
